Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence

The Journal of Urology
Holly E RichterNICHD Pelvic Floor Disorders Network

Abstract

We sought to identify clinical and demographic characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation therapies. We analyzed data from the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial. Baseline participant characteristics and clinical variables were associated with 2 definitions of treatment response, including 1) a reduction in mean daily urgency incontinence episodes during 6 months and 2) a 50% or greater decrease in urgency incontinence episodes across 6 months. The OAB-S (Overactive Bladder-Satisfaction) questionnaire was used to assess satisfaction. A greater reduction in mean daily urgency incontinence episodes was associated with higher HUI-3 (Health Utility Index-3) scores in the onabotulinumtoxinA group and higher baseline incontinence episodes (each p <0.001) in the 2 groups. Increased age was associated with a lesser decrease in incontinence episodes in the 2 groups (p <0.001). Increasing body mass index (adjusted OR 0.82/5 points, 95% CI 0.70-0.96) was associated with reduced achievement of a 50% or greater decrease in incontinence episodes after each treatment. Greater age (adju...Continue Reading

References

Dec 26, 2002·American Journal of Obstetrics and Gynecology·Cindy L Amundsen, George D Webster
Mar 16, 2005·Archives of Internal Medicine·Jennifer L MelvilleKatherine Newton
May 10, 2005·Journal of Clinical Epidemiology·Dianne L GrollJames G Wright
Feb 7, 2006·The Journal of Urology·Catherine E Dubeau
Dec 18, 2007·The Journal of Urology·A I RaginsS K Van Den Eeden
Nov 28, 2008·Clinical Pharmacology and Therapeutics·C E DuBeau
Dec 22, 2009·Neurourology and Urodynamics·Catherine E DuBeauUNKNOWN Fourth International Consultation on Incontinence
Jun 8, 2012·Neurourology and Urodynamics·Kenneth M PetersJudith A Boura
Oct 6, 2012·The New England Journal of Medicine·Anthony G ViscoUNKNOWN Pelvic Floor Disorders Network
May 3, 2013·Obstetrics and Gynecology·Vatche A MinassianFrancine Grodstein
Sep 24, 2013·American Journal of Obstetrics and Gynecology·Heidi S HarvieLily A Arya
Feb 4, 2014·Contemporary Clinical Trials·Cindy L AmundsenSusie Meikle
Jun 23, 2015·JAMA Internal Medicine·Leslee L SubakAlison J Huang
Oct 5, 2016·JAMA : the Journal of the American Medical Association·Cindy L AmundsenSusan F Meikle

❮ Previous
Next ❯

Citations

Jan 6, 2018·International Urogynecology Journal·Samina Tahseen
Nov 7, 2018·Obstetrics and Gynecology·Karen L Noblett, Kristen Buono
Feb 8, 2019·International Urogynecology Journal·Katherine E HuskElizabeth J Geller
Dec 11, 2019·Neurourology and Urodynamics·Christopher ChermanskyArun Sahai
Jan 1, 2020·Zeitschrift für Gerontologie und Geriatrie·Sigrid EgePatrick Roigk
Jun 27, 2020·International Urogynecology Journal·Rachel A HighJill M Danford
Mar 30, 2019·European Urology·Benoit PeyronnetJean-Nicolas Cornu
Dec 4, 2021·Neurourology and Urodynamics·Whitney K HendricksonJ Eric Jelovsek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Botulism (ASM)

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Botulism

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.